Prostaglandin D2 (PGD2) can cause pulmonary vasoconstriction or vasodilation depending on animal species and age. Because the constrictor effects of PGD2 in some vascular beds may be mediated through thromboxane receptors, the purpose of this study was to determine whether the vascular or bronchial effects of PGD2 are mediated through thromboxane/endoperoxide (TX/E) receptor activation. In chronically instrumented awake sheep, PGD2 (5-25 ,ug/kg i.v.) produced a dose-dependent increase in pulmonary arterial pressure and in systemic arterial blood pressure. These changes were due to increases in resistance, because cardiac output remained unchanged. PGD2 also decreased dynamic compliance at lower doses (0.1-5 ,g/kg i.v.) than those required to produce pulmonary vasoconstriction, confirming that PGD2 is a potent bronchoconstrictor. The airway and systemic vascular effects of PGD2 were not altered by TX/E receptor antagonism. In contrast, PGD2-induced pulmonary vasoconstriction was blocked by two TXIE receptor antagonists, SQ-29,548 and AH-23848, implying that this effect is mediated through activation of TX/E receptors. The pulmonary vasoconstrictor effects of PGD2 could not be explained by thromboxane generation, because neither cyclooxygenase inhibition with ibuprofen nor thromboxane synthase inhibition with OKY-046 had any effect on PGD2 actions. In contrast, a mild but consistent pulmonary vasodilation produced by PGD2 could be uncovered if the pulmonary vascular bed was preconstricted by hypoxia with simultaneous TX/E receptor blockade. These results indicate that TX/E receptor antagonists, although still useful pharmacological probes to determine the role of TX/E receptor activation in pathophysiological processes, should not be used to infer a role of endogenous thromboxane A2. It is possible that PGD2 participates in pulmonary processes previously ascribed uniquely to thromboxane A2. (Circulation Research 1991;68:352-358) P rostaglandin D2 (PGD2), a product of the cyclooxygenase pathway of arachidonic acid metabolism, is a major secretory product of activated mast cells' and also is released from lung
. The level of the left atrium was used as the reference for transducer placement. Cardiac output (CO) was measured continuously with the Transonic flow probe and recorded on the strip-chart recorder. CO measurements by flow probe were calibrated to thermodilution CO values (model 9520A cardiac output computer, Edwards Laboratories, Santa Ana, Calif.) by linear regression analysis, using isoproterenol infusion to produce stepwise increases in CO. Pulmonary vascular resistance (PVR) was calculated as (mean PPA-mean PLA)/CO. Mean arterial blood pressure (MABP) was calculated as 1/3 systolic+2/3 diastolic pressure. Total systemic resistance was calculated as MABP/CO. Heart rate was determined from the systemic arterial pressure tracing.
Lung Mechanics
During experiments, a number 10 cuffed Shiley tracheal tube was inserted into the tracheostomy. Airway opening pressure was measured through a multiple-sidehole catheter positioned 0.5 cm beyond the end of the tracheal tube. Pleural pressure was measured directly from the Silastic envelope placed in the pleural space. Transpulmonary pressure was calculated as the difference between airway opening pressure and pleural pressure. All pressure signals were measured using Validyne differential pressure transducers and amplifiers (Validyne Engineering Corp., Northridge, Calif.). Airflow was measured with a Fleisch No. 1 pneumotachograph connected to the tracheal tube. Signals were electronically integrated with a pulmonary mechanics computer (Buxco Electronics, Sharon, Conn.). Dynamic compliance was calculated as tidal volume divided by transpulmonary pressure at points of zero flow and expressed in milliliters per centimeter of water.21 Airflow, tidal volume, transpulmonary pressure, and dynamic compliance were recorded breath-by-breath (recorder 8818, Gould, Cleveland, Ohio) throughout the experiment. Before each set of measurements of lung mechanics, the animals' lungs were inflated to 40 cm H20 airway opening pressure using a tube in water connected to the expiratory port. Materials PGD2 (Cayman Chemical Co. Inc., Ann Arbor, Mich.) was initially dissolved to a concentration of 10 mg/ml in 100% ethanol and stored at -20°C. PGD2 then was diluted in normal saline the day of the study and kept on ice until use. The 1TX/E receptor antagonist SQ-29,548, a generous gift of E.R. Squibb and Sons, Princeton, N.J., was dissolved in 100% ethanol with Trizma Base; approximately 90% of the ethanol was evaporated under nitrogen gas before dilution in normal saline to a concentration of 1 mg/ml. SQ- 29 The doses of receptor blockers and cyclooxygenase inhibitors used here were chosen because they have been shown previously to be effective in this animal model. In particular, we have shown that the dose of ibuprofen used effectively inhibits formation of cyclooxygenase products in sheep. 25 Kubo and Kobayashi23 have shown that OKY-046 at the doses we used inhibits thromboxane formation under identical experimental conditions. Likewise, the dose of SQ-29,548 we used produces a 10-fold shift to the right of the dose-response curve of the thromboxane mimetic U46619 on pulmonary vasoconstriction in unanesthetized sheep.26
To determine if the effects of PGF2a were mediated through TX/E receptor activation, this eicosanoid was infused into the superior vena cava at 25-75 ,ug/kg before and during TX/E receptor blockade with SQ-29,548. Hemodynamic measurements were done as described above.
To determine the effects of PGD2 on the preconstricted pulmonary vascular bed, hypoxic vasoconstriction was induced by connecting the tracheostomy tube to a humidified blended gas reservoir that delivered a gas mixture containing 12% 02-88% N2 until PpA increased to a stable value, usually after 7-10 minutes. 20 Figure 1 ).
Infusion of PGD2 into the left atrium (n=6) also increased PPA, but this increase was of considerably less magnitude than that seen after infusion into the superior vena cava. Furthermore, PVR did not change significantly with left atrium infusions of PGD2. PSA increased after infusion of PGD2 into the left atrium. This increase was similar to that seen after superior vena cava administration (Table 1) .
PGD2 produced a dose-dependent decrease in dynamic compliance (n =5); the duration of the response appeared to be dose-dependent as well. Airways were considerably more responsive to PGD2 than the pulmonary vasculature. The effects of PGD2 on dynamic compliance were already maximal at 5 jig/kg, a dose that had no significant effect on PPA ( Figure 2B ).
Effect of Thromboxane A2/Endoperoxide Receptor Antagonists and Enzyme Inhibitors
To determine if the hemodynamic actions of PGD2
were due to activation of TX/E receptors, two unrelated and selective thromboxane A2 receptor antagonists were used. Both SQ-29,548 (n=6) and AH-23848 (n=5) produced significant blockade of the increase in PPA (Figure 3 ) but had no effect on the systemic vasoconstriction (Figure 2A ) or on the tachycardia produced by PGD2 (changes in heart rate produced by 25 ,g/kg PGD2 were 62± 15 and 51 ± 13 beats/min before and after SQ-29,548, respectively; p>0.05). Likewise, PGD2-induced dynamic compliance was not blocked by SQ-29,548 (n =5, Figure 2B ). thromboxane in the lungs, the effects of PGD2 were compared before and after cyclooxygenase inhibition or thromboxane synthase inhibition. Neither ibuprofen (n=4) nor OXY-046 (n=3) blocked PGD2-induced pulmonary hypertension ( Figure 3 ). They also had no effect on systemic pressure or heart rate changes produced by PGD2. Effect of Prostaglandin D2 in the Preconstricted Pulmonary Vascular Bed To determine if a vasodilatory effect of PGD2 could be uncovered, the effects of PGD2 on the pulmonary vasculature were determined in eight sheep during normoxia, during preconstriction of the pulmonary vasculature with hypoxia, and during Hypoxia increased PPA from 17+1 to 29+2 cm H20. From this higher baseline, PGD2 produced a further increase in PPA when the group was averaged (mean, +8±5 cm H20). However, PGD2 decreased PPA in three of these eight sheep. After a return to baseline on room air, the TX/E receptor antagonist SQ-29,548 was given, and sheep then were made hypoxic again. Pretreatment with SQ-29,548 did not prevent hypoxic vasoconstriction (16±2 to 28 ± 2 cm H20). During combined hypoxia and TX/E blockade, PGD2 decreased PPA in all sheep (mean, -9±2 cm H20, Figure 4) . Effect of Thromboxane A2/Endoperoxide Receptor Antagonisms on the Actions of Prostaglandin F2a
In three sheep, PGF2a produced a dose-dependent increase in PPA and also increased MABP (Table 2) . TX/E receptor antagonism with SQ-29,548 antagonized the effect of PGF2a on the pulmonary vasculature, while having no effect on its systemic actions (Table 2) .
Discussion
In agreement with previous studies, PGD2 produced pulmonary vasoconstriction in adult sheep. This SQ-29,548 and AH-23848, indicating that PGD2-induced pulmonary vasoconstriction is not mediated through activation of DP-receptors but rather through TX/E receptor activation. It could be argued that the TX/E antagonists used also may block DPreceptors. However, the selectivity of these antagonists for TX/E receptors and their lack of effect on DP-receptors is well established.18 Furthermore, these TX/E antagonists blocked only PGD2-induced 60 -
-
A PPA cm H20 20-0-pulmonary vasoconstriction, while having no effect on the other actions of PGD2. It seems unlikely, therefore, that the results could be explained by blockade of DP-receptors. Neither cyclooxygenase inhibition with ibuprofen nor inhibition of thromboxane synthase with OKY-046 prevented the pulmonary vasoconstriction produced by PGD2. Therefore, the possibility that the pulmonary effects of PGD2 could be secondary to The systemic response to PGD2 was not blocked by TX/E receptor antagonists nor by cyclooxygenase or thromboxane synthase inhibitors. In the absence of specific DP-receptor antagonists, we can only speculate on the nature of the receptor that mediates this vasoconstrictive action. Because PGD2 produces vasodilation in most other animal species,15 it is unclear if the vasoconstrictive actions observed in the present study are mediated through DP-receptors. It also is possible that the systemic vasoconstriction was due to conversion of PGD2 into its vasoconstrictive metabolite 9a,11,-PGF2.28 It must be noted that 9a,llfl-PGF2 is the principal in vivo metabolite of PGD2 in humans, and its production increases markedly after systemic mast cell activation. 5, 29 PGD2 produced a dose-dependent decrease in dynamic compliance, in agreement with previous reports indicating PGD2-induced bronchoconstriction.1213 The mechanism of this action is not yet fully understood, because the putative DP-receptor is considered to mediate relaxation of smooth muscle. 15 In the present study, the TX/E receptor antagonist SQ-29,548 had no effect on the PGD2-induced fall in dynamic compliance, while effectively blocking the airways response of U46619, a thromboxane mimetic used as a positive control. This suggests that PGD2 acts on different receptors in the airways than on the pulmonary vasculature. Of interest is the observation that the airways were considerably more sensitive to PGD2-induced constriction than the pulmonary vasculature. This, coupled with the differential effects of TX/E receptor antagonism on the actions of PGD2 on these two types of smooth muscle, further suggests that the receptor that mediates pulmonary vasoconstriction is different from the one that produces bronchoconstriction.
In summary, we have found that PGD2 acts on at least two types of receptors in awake adult sheep. PGD2 produces pulmonary vasoconstriction by activating thromboxane receptors. On the other hand, PGD2 causes potent bronchoconstriction and systemic vasoconstriction through a different prostaglandin receptor, the identification of which will require the development of specific antagonists.30,31 Finally, our results offer further evidence that the vasoconstrictive TX/E receptor is not "specific" for thromboxane, as it can be activated by PGD2 and PGF2a. This implies that TX/E receptor antagonists, although still useful pharmacological probes to determine the role of TX/E receptor activation in pathophysiological processes, should not be used to infer a unique role of endogenous thromboxane A2, as has been previously suggested.22 By the same token, it is possible that PGD2 participates in pulmo-nary processes previously ascribed solely to thromboxane A2 on the basis of studies with receptor antagonists.
